Indian journal of psychological medicine
May 1, 2025
Nikapitiye Nandarathana, Jay Kumar Ranjan
17 citations
A meta-analysis of 21 randomized controlled trials involving 1,470 studies reviewed found that mindfulness-based cognitive therapy (MBCT) effectively reduces symptoms of both anxiety and depressive disorders. The overall standardized mean difference for anxiety was -0.4806 and for depression was -0.3817, indicating moderate effects. Comparisons between postintervention and follow-up showed small, nonsignificant effect sizes for depression (0.0130) and anxiety (0.0198), suggesting that symptom improvements were maintained over time. MBCT produces durable long-term treatment effects for both depressive and anxiety disorders.
Indian journal of psychological medicine
April 29, 2025
Ekta Yadav, Bheemsain Tekkalaki, Kavita P Gadadavar et al.
2 citations
Ketamine infusion therapy, when used alongside other treatments, rapidly reduces depression symptoms in patients with major depressive disorder. In a retrospective chart review of 28 patients at a tertiary care hospital, scores on the Hamilton Depression Rating Scale (HAMD) dropped significantly after an average of 4.6 infusions. More than half of patients (53.6%) showed a therapeutic response—a 50% or greater decrease in HAMD scores—and 39.3% achieved remission, defined as a HAMD score below 7. Suicidal ideation substantially decreased in 71.4% of patients. The findings indicate that ketamine infusion therapy is a safe and effective rapidly acting adjunct treatment for depression.
Indian journal of psychological medicine
January 22, 2026
Zaid Ahmad Wani, Rajnish Raj, Shabir Ahmad Dar et al.
In a retrospective study of 41 patients in India with major depressive disorder, bipolar depression, or suicidal ideation, oral ketamine therapy was associated with significant reductions in both depressive symptoms and suicidal thoughts. Depression severity, measured by the Hamilton Depression Rating Scale, decreased by an average of 8.19 points, and suicidal ideation, measured by the Modified Scale for Suicidal Ideation, decreased by an average of 4.95 points after three sessions. Common side effects included dizziness, nausea, and hypertension; diarrhea was least common. The findings suggest oral ketamine is an effective and well-tolerated rapid-acting option for reducing depressive symptoms and suicidality, suitable for outpatient use in the Indian context.
Indian journal of psychological medicine
November 13, 2025
Malika M Sanspara, Drashti M Shah, Sandip H Shah et al.
A single intramuscular injection of ketamine (0.5 mg/kg) rapidly reduces suicidal ideation in adults, with a 78% decrease in MADRS-SI scores within two hours and 76% of patients reporting no suicidal ideation. Among 38 patients, 89% of those completing one-month follow-up maintained the reduction. Most patients required only one injection, though 36% needed multiple doses. Common side effects were dizziness and sedation, but no serious adverse events occurred. The study suggests IM ketamine is a safe and effective fast-acting option for suicidal ideation in settings where intravenous treatment is impractical.
Indian journal of psychological medicine
July 2, 2025
Sonal Agarwal, Shahzadi Malhotra, Vibha Sharma et al.
Young adults diagnosed with dissociative disorder show poorer performance on tests of executive function, inhibitory control, and verbal memory compared to healthy controls, though some neuropsychological domains did not differ. The study compared 30 individuals with dissociative disorder and 30 healthy controls aged 18-30 in North India. Those with the disorder scored higher on the Dissociative Experiences Scale, indicating more dissociative experiences. Moderate associations were found between executive functioning, verbal memory, inhibitory control, and dissociative experiences. These findings highlight the link between neuropsychological factors and dissociative disorders in an Indian population, which may inform clinical assessments and interventions.